REMICADE 100 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION

USDailyMed:Infliximab AU:C L04AB02(WHO) AU:S4(Prescription only)CA:℞-only/ Schedule DUK:POM(Prescription only)US:℞-onlyEU:Rx-only 170277-31-3Y DB00065Y none B72HH48FLU D02598Y ChEMBL1201581N DTXSID9040504 Infliximab, a chimeric monoclonal antibody, sold under the brand nameRemicadeamong others, is a medication used to treat a number ofautoimmune diseases. This includesCrohn's disease,ulcerative colitis,rheumatoid arthritis,ankylosing spondylitis,psoriasis,psoriatic arthritis, andBehçet's disease.It is given byslow injection into a vein, typically at six- to eight-week intervals. Common side effects include infections,acute infusion reactions, and abdominal pain.Infliximab is achimericmonoclonal antibodybiologic. It seems to work by binding to and neutralizingTNF, preventing it from interacting with itsreceptorson the cell.TNF is a chemical messenger (cytokine) and a key part of the autoimmune reaction. Infliximab was originally developed in mice as a mouse antibody. Because humans have immune reactions to mouse proteins, the mouse common domains were replaced with similar human antibody domains. They aremonoclonal antibodiesand have identical structures and affinities to the target. Because they are a combination of mouse and human antibody amino acid sequences, they are called a "chimeric monoclonal antibody".[medical citation needed] Infliximab was approved for medical use in the United States in 1998,and in the European Union in August 1999.Infliximabbiosimilarshave been approved in the EU (2013), in Japan (2014), and in the United States (2016, 2017, 2019).Infliximab is a therapeutic alternative on theWorld Health Organization's List of Essential Medicines.